News

ITI-214 showed favorable safety with early signs of improvement in motor symptoms for patients with Parkinson disease

The director of the Center of Neurogenetics at Weill Cornell Medicine spoke about the wealth of improvements that have really turned this area of medicine into a much more hopeful one.

The Associate Clinical Professor at the University of South Carolina School of Medicine and Chief Medical Officer at SleepMed emphasized that clinicians need to recognize the impact of sleepiness in terms of quality of life.

"If Mom would just let me play video games again, I would feel better.”

The CGRP inhibitors are poised to transform the treatment paradigm for patients with migraine and cluster headache.

The Global Medical Lead for Migraine and Headache at Teva Pharmaceuticals, the therapy’s developer, discussed its performance in patients with medication overuse headache.

VY-AADC01 demonstrated promising early signs of activity and safety for patients with Parkinson disease.

The assistant professor of neurology at the University of Pennsylvania discussed the complication of cognitive issues faced by patients with epilepsy, and how these are being addressed in the clinic.

Impairment of physiological spindle activity in the hippocampus during NREM sleep by interictal epileptic activities may have negative consequences on long-term memory consolidation.

Henchcliffe discussed the progress that has been made in this area, and where things are headed going forward.

Several novel therapies in early stage development are beginning to show promise for patients with Huntington disease.

The director of the Pediatric Movement Disorders Program at UT Southwestern spoke about the ability of advanced imaging to help better understand the causes of disease.

Since the inception of the idea more than 3 decades ago and its initial development 20 years later, Sarepta Therapeutics’ micro-dystrophin gene therapy has now made its way to human trials.

Those suffering from significant emotional distress and sleep disturbances may benefit from targeted interventions to restore consolidated REM sleep or prevent the occurrence of fragmented REM sleep.

Both doses of lemborexant reduced subjective sleep onset latency for patients with insomnia.

The medical director of the UCSF Multiple Sclerosis Center provided some insight into the development of therapies for the purpose of remyelination.

Neurology News Network for the week of October 20, 2018.

The gene therapy is also being assessed for long-term safety data, as well as an additional delivery method.

The director of the Comprehensive Multiple Sclerosis Center at Thomas Jefferson University discussed the concept of lymphocyte depletion to reset the immune system.

Patients under the age of 65 were not shown to derive benefit from DBS, but researchers noted that this doesn’t mean it is not helpful for older patients.

With more than a dozen available therapies, disease-modification in multiple sclerosis is entering a new era of development.

Stem cell tourism is a global problem. The top three conditions marketed by such clinics are MS, PD, and stroke-often peddling false hope to patients who are vulnerable, desperately searching for a cure. 

The smartphone application-led program, Floodlight Open, recently initiated in the US and Canada.

Results suggested that for every 1% of brain volume lost, a 51.7% increase in risk of clinically definite MS conversion was observed.

Several agents are currently in development geared at the relief of off-time for patients with Parkinson.

The goal of the free application is to make cognitive assessments routine in multiple sclerosis treatment.

The next important area of therapeutic development in MS appears to be in disease damage repair.

Cannabinoids are being explored in a variety of conditions, ranging from Alzheimer disease to migraine.